Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Tyk2

Tyk2

Brief Information

Name:Tyrosine-protein kinase 2
Target Synonym:EC:2.7.10.2,TYK2,Tyrosine Kinase 2,Non-Receptor Tyrosine-Protein Kinase TYK2,EC 2.7.10.2,IMD35,JTK1,TYK2 Kinase,EC 2.7.10
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TY2-H5547 Human Human Tyk2 Protein, His Tag (active enzyme)
TY2-H5547-structure
TY2-H5548 Human Human Tyk2 Protein, His Tag
TY2-H5548-structure
TY2-H5548-sds
ACRO Quality

Synonym Name

Tyk2,tyrosine kinase 2

Background

Tyk2 was the first member of the JAK family that was described (the other members are JAK1, JAK2, and JAK3). It has been implicated in IFN-?, IL-6, IL-10 and IL-12 signaling. Tyk2 functions primarily in IL-12 and type I-IFN signaling. Tyk2 deficiency has more dramatic effects in human cells than in mouse cells. However, in addition to IFN-? and -? and IL-12 signaling, Tyk2 has major effects on the transduction of IL-23, IL-10, and IL-6 signals. Recently, it has been recognized that IL-12 and IL-23 share ligand and receptor subunits that activate Tyk2. Tyk2 is activated by IL-10, and its deficiency affects the ability to generate and respond to IL-10.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Peficitinib ASP-015K; JNJ-54781532 Approved Astellas Pharma Inc Smyraf Japan Arthritis, Rheumatoid Astellas Pharma Inc 2019-03-29 Arthritis, Rheumatoid; Psoriasis; Colitis, Ulcerative Details
Deucravacitinib BMS-986165; BMS-986165-01 Approved Bristol-Myers Squibb Company Sotyktu Japan Psoriasis Bristol-Myers Squibb Kk 2022-09-09 Lupus Vulgaris; Inflammatory Bowel Diseases; Alopecia Areata; Lupus Erythematosus, Discoid; Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lupus Nephritis; Liver Diseases; Psoriasis; Lupus Erythematosus, Systemic; Colitis, Ulcerative; Arthritis, Psoriatic; Inflammation; Crohn Disease; Plaque psoriasis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ABBV-712 ABBV-712 Phase 1 Clinical Abbvie Inc Psoriasis Details
MAX-40070 MAX-40070 Phase 1 Clinical Maxinovel Pty Ltd Alopecia Areata Details
GLPG-3121 GLPG-3121 Phase 1 Clinical Galapagos Nv Details
BGB-23339 BGB-23339 Phase 1 Clinical Beigene Ltd Autoimmune Diseases; Plaque psoriasis Details
OST-122 OST-122 Phase 2 Clinical Oncostellae Sl Colitis, Ulcerative Details
TLL-018 TLL-018 Phase 2 Clinical Tll Pharmaceutical Llc Chronic Urticaria; Arthritis, Rheumatoid; Psoriasis; Colitis, Ulcerative; Urticaria Details
TQ-05105 TQ-05105 Phase 2 Clinical Lianyungang Runzhong Pharmaceutical Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Centaurus Biopharma Co Ltd Myeloproliferative Disorders; Neoplasms; Graft vs Host Disease; Primary Myelofibrosis; Lymphohistiocytosis, Hemophagocytic Details
ICP-488 ICP-488 Phase 1 Clinical InnoCare Pharma Ltd Autoimmune Diseases; Psoriasis; Plaque psoriasis Details
ESK-001 ESK-001 Phase 2 Clinical Alumis Inc Autoimmune Diseases; Psoriasis Details
QY201 QY-201; QY201 Phase 2 Clinical E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd Alopecia Areata; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Dermatitis, Atopic Details
ICP-332 ICP-332 Phase 1 Clinical InnoCare Pharma Ltd Psoriasis; Dermatitis, Atopic Details
Brepocitinib PF-06700841-15; PF-6700841; PF-841; PF-06700841 Phase 3 Clinical Pfizer Inc Alopecia; Alopecia Areata; Dermatomyositis; Kidney Diseases; Lupus Erythematosus, Systemic; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic; Hidradenitis Suppurativa; Dermatitis, Atopic; Vitiligo; Crohn Disease Details
Ropsacitinib PF-06826647 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Psoriasis; Colitis, Ulcerative; Hidradenitis Suppurativa Details
VTX-958 VTX-958 Phase 2 Clinical Ventyx Biosciences Inc Plaque psoriasis Details
NDI-034858 NDI-034858 Phase 2 Clinical Nimbus Therapeutics LLC Psoriasis; Arthritis, Psoriatic; Plaque psoriasis Details
GLPG-3667 GLPG-3667 Phase 1 Clinical Galapagos Nv Psoriasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message